Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/18 – ‘EXCEL’

On:  Tuesday, 12/11/18, at 4:48pm ET   ·   For:  9/30/18   ·   Accession #:  1615774-18-14245   ·   File #:  1-35527

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    930K 
 2: EX-10.13    Material Contract                                   HTML     54K 
 3: EX-10.14    Material Contract                                   HTML     53K 
 4: EX-10.15    Material Contract                                   HTML     37K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
16: R1          Document and Entity Information                     HTML     58K 
17: R2          Consolidated Balance Sheets                         HTML    126K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
19: R4          Consolidated Statements of Operations               HTML     78K 
20: R5          Consolidated Statements of Changes in Equity        HTML    104K 
21: R6          Consolidated Statements of Cash Flows               HTML    119K 
22: R7          Consolidated Statements of Cash Flows               HTML     24K 
                (Parenthetical)                                                  
23: R8          Nature of Operations                                HTML     32K 
24: R9          Summary of Significant Accounting Policies          HTML     90K 
25: R10         Accounts Receivable, Net                            HTML     27K 
26: R11         Long - Term Borrowings and Other Note Payables      HTML     26K 
27: R12         Acquisition                                         HTML     47K 
28: R13         Stockholders' Equity                                HTML    207K 
29: R14         Convertible Preferred Stock                         HTML     39K 
30: R15         Income Taxes                                        HTML     67K 
31: R16         Related Party Transactions                          HTML     29K 
32: R17         Loss Per Share                                      HTML     37K 
33: R18         Commitments and Contingent Liabilities              HTML     33K 
34: R19         Significant Customers                               HTML     23K 
35: R20         Subsequent Events                                   HTML     32K 
36: R21         Summary of Significant Accounting Policies          HTML    165K 
                (Policies)                                                       
37: R22         Summary of Significant Accounting Policies          HTML     26K 
                (Tables)                                                         
38: R23         Accounts Receivable, Net (Tables)                   HTML     28K 
39: R24         Acquisition (Tables)                                HTML     46K 
40: R25         Stockholders' Equity (Tables)                       HTML    176K 
41: R26         Income Taxes (Tables)                               HTML     67K 
42: R27         Loss Per Share (Tables)                             HTML     37K 
43: R28         Commitments and Contingent Liabilities (Tables)     HTML     28K 
44: R29         Nature of Operations (Details Narrative)            HTML     32K 
45: R30         Summary of Significant Accounting Policies          HTML     32K 
                (Details )                                                       
46: R31         Summary of Significant Accounting Policies          HTML     31K 
                (Details Narrative)                                              
47: R32         Summary of Significant Accounting Policies          HTML     71K 
                (Details Narrative 1)                                            
48: R33         Accounts Receivable, Net (Details)                  HTML     29K 
49: R34         Long - Term Borrowings and Other Note Payables      HTML     48K 
                (Details Narrative)                                              
50: R35         Acquisition (Details)                               HTML     67K 
51: R36         Acquisition (Details 1)                             HTML     29K 
52: R37         Acquisition (Details Narrative)                     HTML     57K 
53: R38         Stockholders' Equity (Details)                      HTML     34K 
54: R39         Stockholders' Equity (Details 1)                    HTML     27K 
55: R40         Stockholders' Equity (Details 2)                    HTML     56K 
56: R41         Stockholders' Equity (Details 3)                    HTML    123K 
57: R42         Stockholders' Equity (Details 4)                    HTML     50K 
58: R43         Stockholders' Equity (Details 5)                    HTML     34K 
59: R44         Stockholders' Equity (Details 6)                    HTML     43K 
60: R45         Stockholders' Equity (Details 7)                    HTML     63K 
61: R46         Stockholders' Equity (Details Narrative)            HTML    215K 
62: R47         Stockholders' Equity (Details Narrative 1)          HTML    101K 
63: R48         Convertible Preferred Stock (Details Narrative)     HTML     59K 
64: R49         Income Taxes (Details)                              HTML     45K 
65: R50         Income Taxes (Details 1)                            HTML     40K 
66: R51         Income Taxes (Details 2)                            HTML     44K 
67: R52         Income Taxes (Details 3)                            HTML     42K 
68: R53         Income Taxes (Details Narrative)                    HTML     36K 
69: R54         Related Party Transactions (Details Narrative)      HTML     61K 
70: R55         Loss Per Share (Details)                            HTML     48K 
71: R56         Commitments and Contingent Liabilities (Details)    HTML     25K 
72: R57         Commitments and Contingent Liabilities (Details     HTML     42K 
                Narrative)                                                       
73: R58         Significant Customers (Details Narrative)           HTML     31K 
74: R59         Subsequent Events (Details Narrative)               HTML     60K 
76: XML         IDEA XML File -- Filing Summary                      XML    131K 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX    100K 
10: EX-101.INS  XBRL Instance -- mynd-20180930                       XML   1.87M 
12: EX-101.CAL  XBRL Calculations -- mynd-20180930_cal               XML    199K 
13: EX-101.DEF  XBRL Definitions -- mynd-20180930_def                XML    782K 
14: EX-101.LAB  XBRL Labels -- mynd-20180930_lab                     XML   1.28M 
15: EX-101.PRE  XBRL Presentations -- mynd-20180930_pre              XML   1.00M 
11: EX-101.SCH  XBRL Schema -- mynd-20180930                         XSD    198K 
77: ZIP         XBRL Zipped Folder -- 0001615774-18-014245-xbrl      Zip    174K 

‘EXCEL’   —   IDEA Workbook of Financial Reports

This is an IDEA Workbook.

Download this Microsoft® Excel® .xlsx workbook

7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/23  Emmaus Life Sciences, Inc.        10-K       12/31/22   88:18M                                    Donnelley … Solutions/FA
 3/31/22  Emmaus Life Sciences, Inc.        10-K       12/31/21   98:18M                                    ActiveDisclosure/FA
 8/10/21  Emmaus Life Sciences, Inc.        10-K/A     12/31/20   92:18M                                    ActiveDisclosure/FA
 5/04/21  Emmaus Life Sciences, Inc.        10-K       12/31/20   97:18M                                    ActiveDisclosure/FA
 1/25/21  Emmaus Life Sciences, Inc.        10-K       12/31/19  121:29M                                    ActiveDisclosure/FA
 5/30/19  SEC                               UPLOAD¶     6/27/19    2:45K  Emmaus Life Sciences, Inc.
 5/02/19  SEC                               UPLOAD¶     6/27/19    2:53K  Emmaus Life Sciences, Inc.